Company intelligence / Profile preview

Lin BioScience, Inc.

Ownership: Private
Development stage: Phase 3

Overview

LBS-007 received FDA Fast Track Designation for acute myeloid leukemia treatment in November 2024. Currently conducting a phase 1/2 trial in patients with relapsed or resistant acute leukemias in the US, Australia, and Taiwan. LBS-008 has initiated phase 3 trials for Stargardt disease.

Therapeutic areas: GastroenterologyOncologyOphthalmologyEndocrinologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

granaticin b

2 more assets in the full pipeline.

Request access →

Partnerships

NIH Blueprint Program (BPN)Taiwan Industrial Development Bureau's Innovation Platform Program

Beyond the preview

Go deeper on Lin BioScience, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lin BioScience, Inc..

Explore the full profile